Perkembangan Terkini Terapi Antikoagulan Pada Pasien Covid-19 Bergejala Berat

Taofik Rusdiana, Rizki Akbar

Abstrak


Penyakit covid-19 yang disebabkan oleh virus sarcov-2 awalnya hanya dinyatakan sebagai penyakit pernafasan, namun kemudian diketahui dampak dari penyakit ini dapat menyebabkan kerusakan multiorgan karena adanya fenomeda badai sitokin yang menyebabkan inflamasi dimana-mana termasuk pada pembuluh darah yang menuju berbagai organ penting. Tulisan ini bertujuan untuk mengungkap seberapa signifikan fenomeda koagulasi darah hasil kerja virus covid-19 ini hingga menyebabkan manifestasi tromboembolisme baik dalam terminologi tromboemboli vena, deep vein thrombosis, tromboemboli paru dan lain-lain, juga kemungkinan mekanisme yang terjadi dan yang terpenting dalam tulisan ini adalah seberapa efektifkah penggunaan obat antikoagulan pada pasien covid-19 bergejala berat.


Kata Kunci


Covid-19; sarcov-2; antikaogulan; tromboemboli; heparin.

Teks Lengkap:

PDF

Referensi


Long, B, Brady, WJ, Koyfman, A, and Gottlieb, M. Cardiovascular complications in COVID-19. Am J Emerg Med. 2020;38(7):1504-07. https://doi.org/10.1016/ j.ajem.2020.04.048.

Bansal, M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr. 2020;14(3):247-50. https://doi.org/10.1016/j.dsx.2020.03.013.

He, XW, et al. [Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48(6):456-60. https://doi.org/10.3760/cma.j.cn112148-20200228-00137.

Tam, CF, et al. Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on ST-Segment-Elevation Myocardial Infarction Care in Hong Kong, China. Circ Cardiovasc Qual Outcomes. 2020;13(4):e006631. https://doi.org/10.1161/circoutcomes.120.006631.

Lee, IC, Huo, TI, and Huang, YH. Gastrointestinal and liver manifestations in patients with COVID-19. J Chin Med Assoc. 2020;83(6):521-23. https://doi.org/10.1097/jcma.0000000000000319.

Garrido, I, Liberal, R, and Macedo, G. Review article: COVID-19 and liver disease-what we know on 1st May 2020. Aliment Pharmacol Ther. 2020;52(2):267-75. https://doi.org/10.1111/apt.15813.

Adapa, S, et al. COVID-19 Pandemic Causing Acute Kidney Injury and Impact on Patients With Chronic Kidney Disease and Renal Transplantation. J Clin Med Res. 2020;12(6):352-61. https://doi.org/10.14740/jocmr4200.

Gabarre, P, et al. Acute kidney injury in critically ill patients with COVID-19. Intensive Care Med. 2020;46(7):1339-48. https://doi.org/10.1007/s00134-020-06153-9.

Hayek, SS, et al. In-hospital cardiac arrest in critically ill patients with covid-19: multicenter cohort study. BMJ. 2020;371:m3513. https://doi.org/10.1136/bmj.m3513.

Cui, S, Chen, S, Li, X, Liu, S, and Wang, F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. Journal of thrombosis and haemostasis : JTH. 2020;18(6):1421-24. https://doi.org/10.1111/jth.14830.

Klok, FA, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis research. 2020;191:145-47. https://doi.org/10.1016/ j.thromres.2020.04.013.

Klok, FA, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res. 2020;191:148-50. https://doi.org/10.1016/j.thromres.2020.04.041.

Ren, B, et al. Extremely High Incidence of Lower Extremity Deep Venous Thrombosis in 48 Patients With Severe COVID-19 in Wuhan. Circulation. 2020;142(2):181-83. https://doi.org/10.1161/circulationaha.120.047407.

Belen-Apak, FB and Sarialioglu, F. Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy. J Thromb Thrombolysis. 2020;50(2):278-80. https://doi.org/10.1007/s11239-020-02129-0.

Artifoni, M, et al. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors. J Thromb Thrombolysis. 2020;50(1):211-16. https://doi.org/10.1007/s11239-020-02146-z.

Llitjos, J-F, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. Journal of thrombosis and haemostasis : JTH. 2020;18(7):1743-46. https://doi.org/10.1111/jth.14869.

Lodigiani, C, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9-14. https://doi.org/10.1016/j.thromres.2020.04.024.

Maatman, TK, et al. Routine Venous Thromboembolism Prophylaxis May Be Inadequate in the Hypercoagulable State of Severe Coronavirus Disease 2019. Crit Care Med. 2020;48(9):e783-e90. https://doi.org/10.1097/ccm.0000000000004466.

Middeldorp, S, et al. Incidence of venous thromboembolism in hospitalized patients with COVID‐19. Journal of Thrombosis and Haemostasis. 2020;18(8):1995-2002. https://doi.org/10.1111/jth.14888.

Han, H, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020;58(7):1116-20. https://doi.org/10.1515/cclm-2020-0188.

Shi, L, Wang, Y, Wang, YD, Duan, GC, and Yang, HY. D-dimer is associated with the risk of mortality in Coronavirus Disease 2019 patients. Eur Rev Med Pharmacol Sci. 2020;24(16):8576-79. https://doi.org/10.26355/eurrev_202008_22655.

Al-Samkari, H, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020;136(4):489-500. https://doi.org/ 10.1182/blood.2020006520.

Cheng, A, et al. Diagnostic performance of initial blood urea nitrogen combined with D-dimer levels for predicting in-hospital mortality in COVID-19 patients. International journal of antimicrobial agents. 2020;56(3):106110-10. https://doi.org/10.1016/j.ijantimicag.2020.106110.

Sakka, M, et al. Association between D-Dimer levels and mortality in patients with coronavirus disease 2019 (COVID-19): a systematic review and pooled analysis. Journal de medecine vasculaire. 2020;45(5):268-74. https://doi.org/10.1016/ j.jdmv.2020.05.003.

Tang, N, Li, D, Wang, X, and Sun, Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of thrombosis and haemostasis : JTH. 2020;18(4):844-47. https://doi.org/10.1111/jth.14768.

Wu, C, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA internal medicine. 2020;180(7):934-43. https://doi.org/10.1001/jamainternmed. 2020.0994.

Zhang, L, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. Journal of thrombosis and haemostasis : JTH. 2020;18(6):1324-29. https://doi.org/10.1111/jth.14859.

Price, LC, McCabe, C, Garfield, B, and Wort, SJ. Thrombosis and COVID-19 pneumonia: the clot thickens! The European respiratory journal. 2020;56(1):2001608. https://doi.org/10.1183/13993003.01608-2020.

Pizzolo, F, et al. Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg. Thrombosis Research. 2020;194:216-19. https://doi.org/10.1016/j.thromres.2020.08.008.

Aid, M, et al. Vascular Disease and Thrombosis in SARS-CoV-2 Infected Rhesus Macaques. Cell. 2020. https://doi.org/ https://doi.org/10.1016/j.cell.2020.10.005.

Rico-Mesa, JS, et al. The Role of Anticoagulation in COVID-19-Induced Hypercoagulability. Current cardiology reports. 2020;22(7):53-53. https://doi.org/ 10.1007/s11886-020-01328-8.

Kollias, A, et al. Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action. Br J Haematol. 2020;189(5):846-47. https://doi.org/10.1111/bjh.16727.

Tang, N, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094-99. https://doi.org/10.1111/jth.14817.

Paranjpe, I, et al. Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19. J Am Coll Cardiol. 2020;76(1):122-24. https://doi.org/10.1016/j.jacc.2020.05.001.

DeSancho, MT. Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial) (IMPACT). 2020 [cited 2020 october 10]; Available from: https://clinicaltrials.gov/ct2/show/NCT04406389.




DOI: https://doi.org/10.25077/jsfk.7.3.244-250.2020

Article Metrics

Abstract view : 1632 times
PDF view/download : 2959 times



Jurnal Sains Farmasi & Klinis (J Sains Farm Klin) | p-ISSN: 2407-7062 | e-ISSN: 2442-5435

Diterbitkan oleh Fakultas Farmasi Universitas Andalas bekerjasama dengan Ikatan Apoteker Indonesia - Daerah Sumatera Barat 

      

 JSFK is licensed under Creative Commons Attribution-ShareAlike 4.0 International License.